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faecal microbiota transplantation with
antibiotics for treatment of recurrent
Clostridioides difficile infection: a systematic
review
Lianna Hede Hammeken1* , Simon Mark Dahl Baunwall2, Christian Lodberg Hvas2 and Lars Holger Ehlers1
Abstract
Background: Faecal microbiota transplantation (FMT) is increasingly being used in the treatment of recurrent
Clostridioides difficile infection (rCDI). Health economic evaluations may support decision-making regarding the
implementation of FMT in clinical practice. Previous reviews have highlighted several methodological concerns in
published health economic evaluations examining FMT. However, the impact of these concerns on the conclusions
of the studies remains unclear.
Aims: To present an overview and assess the methodological quality of health economic evaluations that compare
FMT with antibiotics for treatment of rCDI. Furthermore, we aimed to evaluate the degree to which any
methodological concerns would affect conclusions about the cost-effectiveness of FMT.
Methods: We conducted a systematic literature review based on a search in seven medical databases up to 16 July
2020. We included research articles reporting on full health economic evaluations comparing FMT with antibiotic
treatment for rCDI. General study characteristics and input estimates for costs, effectiveness and utilities were extracted
from the articles. The quality of the studies was assessed by two authors using the Drummonds ten-point checklist.
Results: We identified seven cost-utility analyses. All studies applied decision-analytic modelling and compared various
FMT delivery methods with vancomycin, fidaxomicin, metronidazole or a combination of vancomycin and
bezlotoxumab. The time horizons used in the analyses varied from 78 days to lifelong, and the perspectives differed
between a societal, a healthcare system or a third-party payer perspective. The applied willingness-to-pay threshold
ranged from 20,000 to 68,000 Great Britain pound sterling (GBP) per quality-adjusted life-year (QALY). FMT was
considered the most cost-effective alternative in all studies. In five of the health economic evaluations, FMT was both
more effective and cost saving than antibiotic treatment alternatives. The quality of the articles varied, and we
identified several methodological concerns.
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Conclusions: Economic evaluations consistently reported that FMT is a cost-effective and potentially cost-saving
treatment for rCDI. Based on a comparison with recent evidence within the area, the multiple methodological
concerns seem not to change this conclusion. Therefore, implementing FMT for rCDI in clinical practice should be
strongly considered.
Keywords: Systematic review, Economic evaluation, Fecal microbiota transplantation, Faecal microbiota transplantation,
Anti-bacterial agents, Decision making, Clinical decision-making
Background
Clostridioides difficile infection (CDI) is an enteric infec-
tion causing symptoms ranging from diarrhoea and ab-
dominal discomfort to toxic megacolon and death [1, 2].
In Europe, the incidence rate for healthcare-associated
CDI has been estimated to 23 per 10,000 admissions [3].
The standard treatment for CDI is antibiotics, but 20–
30% fail to achieve a sustained response and suffer re-
currence [4, 5].
Current clinical guidelines recommend oral vancomycin
or oral fidaxomicin for the first recurrence of CDI (rCDI)
and pulse/taper oral vancomycin, fidaxomicin or faecal
microbiota transplantation (FMT) for any subsequent re-
current episodes [6, 7]. FMT is a novel procedure by
which minimally processed faeces from a thoroughly
screened healthy donor is transferred to a patient to cor-
rect a disrupted intestinal microbiota [8]. During the past
decade, FMT has gained widespread recognition as a
highly effective treatment for rCDI; effect rates exceeding
90% for FMT have been reported in observational studies
[9, 10], and randomised controlled trials (RCTs) have
found FMT to be comparable [11] or superior to anti-
biotic treatments for patients with rCDI [12–14].
Healthcare systems worldwide are currently facing in-
creasing budgetary pressures due to an ageing popula-
tion and expensive medical treatments [15], and the
need is rising to include both clinical and economic con-
siderations in the decision-making when implementing
new technologies [16]. Health economic evaluations may
help qualify these decisions by providing an analysis of
the costs and consequences of two or more alternative
technologies [16]. Given the growing interest in the use
of FMT for rCDI treatment [17], it becomes important
to support healthcare decision-making regarding the im-
plementation of FMT in clinical practice. Previous sys-
tematic reviews have evaluated the cost-effectiveness of
providing FMT for both index CDI and rCDI and have
highlighted several concerns about the methodological
quality of existing health economic evaluations [18, 19].
However, the impact of these concerns on the conclu-
sions of the studies has yet to be evaluated.
The present study aimed to present an overview of
and to assess the quality of health economic evaluations
that compare FMT with antibiotics in the treatment of
rCDI based on a systematic literature review. We further
aimed to evaluate how any methodological concerns
would affect the conclusions about cost-effectiveness
based on a comparison with recent evidence within the
area, and thereby hope to provide clear guidance for
healthcare decision-makers.
Materials and methods
This systematic review was conducted in accordance
with the PRISMA guidelines for reporting of systematic
reviews and meta-analyses [20].
Eligibility criteria
Predefined criteria were applied to identify relevant stud-
ies. We included full health economic evaluations com-
paring FMT with any antibiotic treatment strategy for
rCDI. A health economic evaluation was defined as a
study comparing both the costs and consequences of al-
ternative treatments, i.e. cost-benefit, cost-effectiveness
or cost-utility analyses [16]. We excluded studies includ-
ing only costs or consequences and article types other
than research articles, e.g. reviews, editorials and confer-
ence abstracts.
Search strategy
A systematic literature search was conducted up to 16
July 2020 for all available literature in the following data-
bases: PubMed, Embase, the Cochrane Library, Cinahl,
Scopus, EconLit and the NHS Economic Evaluation
Database. If the database allowed it, the search was lim-
ited to English and Danish language. No other restric-
tions were made. A combination of the following search
terms was applied: ‘Clostridium difficile infection’ AND
‘fecal microbiota transplantation’ AND (‘economic
evaluation’ OR ‘cost-benefit’ OR ‘cost-effectiveness’ OR
‘cost-utility’). The search terms were adjusted to the spe-
cific databases and consisted of a combination of the-
saurus terms and free-text search. The authors have
previously reported a preliminary study using a similar
search strategy in a conference abstract [21]. The
complete search strategy used in the present systematic
review is available in Additional file 1.
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Study selection
After searching the specified databases, duplicates were
removed using the reference managing software Ref-
Works (ProQuest, Michigan, USA). Remaining dupli-
cates were identified by comparing the title, author, year
and journal of the studies and were manually removed.
After the exclusion of duplicates, records were screened
for inclusion based on the title and abstract. The full text
of the remaining studies was then assessed. Two authors
(LHH and SMDB) independently conducted the screen-
ing and assessment for inclusion of records, and any dis-
agreements were resolved by dialogue between the two
authors.
Data extraction
The following data on study characteristics were ex-
tracted from the included records: author and year of
publication, setting, analytic method, time horizon, per-
spective, outcome measure, patient population, interven-
tion, control treatment, willingness-to-pay threshold,
results and the conclusion regarding cost-effectiveness.
Also, input estimates applied for utilities, effectiveness
and costs were extracted to a separate table. Costs were
both presented as original values and converted to 2019-
level Great Britain pound sterling (GBP). Extrapolation
was done by applying a country-specific consumer price
index [22]. Afterwards, purchasing power parity adjusted
exchange rates were used to convert the estimates into
GBP [23].
Quality assessment
Methodological quality was assessed using the Drum-
mond ten-point checklist for assessing economic evalua-
tions [16]. The checklist consists of ten essential items
and several subitems related to, e.g., the research aim
and choice of comparators, the effectiveness measure,
costs and outcome measures as well as the results and
uncertainties of the analysis [16]. Two authors (LHH
and LHE) assessed each of the studies and agreed on a
final assessment. The results from the quality assessment
were reported for each checklist item and categorised
into the following four answers: yes (adequate), no (not
adequate), cannot tell (unclear) or not applicable based
on compliance with the checklist.
Results
Study selection
A total of 272 records were identified in the systematic
literature search (Fig. 1). Fifty-one duplicates were re-
moved, and the remaining 221 records were screened
based on the eligibility criteria. Among these, 207 were
excluded as they were not full health economic evalua-
tions, did not compare FMT with antibiotic treatment or
did not focus on rCDI. Thus, the full text of a total of 14
records was screened, and seven of these were included
in the systematic review [24–30].
Study characteristics
A schematic presentation of the general study character-
istics is provided in Additional file 2. The studies origi-
nated from the United States (n = 3) [24, 25, 29], Canada
(n = 1) [26], Australia (n = 1) [27], France (n = 1) [28]
and the United Kingdom (n = 1) [30] and were published
between 2014 and 2020. All studies were cost-utility
analyses based on decision-analytic modelling using ei-
ther decision trees (n = 4) [24, 25, 28, 29] or Markov
models (n = 3) [26, 27, 30]. The number of previous
rCDI episodes differed between studies, ranging from
the first to the third rCDI at inclusion.
All studies included FMT administered by colonos-
copy, and some also included nasoduodenal/−gastric in-
fusion (n = 5) [24, 26–28, 30], enema (n = 3) [24, 26, 28]
or oral capsules (n = 1) [29]. The treatment of additional
recurrences was either reported as repeat FMT or a shift
to oral vancomycin. In all studies, the control treatment
was oral vancomycin in different dosages and treatment
regimens. Fidaxomicin was applied in most studies (n =
5) [24, 26, 28–30], whereas two studies included oral
metronidazole [24, 26], and one study included the com-
bination of oral vancomycin with bezlotoxumab [29]. In
case of additional recurrences, the subsequent antibiotic
treatment strategies differed in accordance with the
number of previous rCDI episodes.
The studies either applied a relatively short time hori-
zon of 78 days to 1 year (n = 5) [24, 25, 28–30] or a life-
long time horizon (n = 1) [26], whereas the reported
perspectives differed between a societal (n = 2) [24, 28], a
third-party payer (n = 2) [25, 29] and a healthcare system
perspective (n = 2) [26, 30]. The willingness-to-pay
threshold ranged from 20,000 to 68,000 GBP per
quality-adjusted life-year (QALY).
FMT was estimated as the most cost-effective alterna-
tive in all studies. In five of the health economic evalua-
tions, FMT strongly dominated, i.e. was both cost-saving
and more effective than all the antibiotic treatment alter-
natives [25–27, 29, 30]. However, the results differed
with respect to FMT delivery method; FMT by colonos-
copy was cost-effective in four of the studies [24–26,
29], whereas FMT by nasoduodenal/−gastric infusion
was cost-effective in two studies [27, 30], and FMT by
enema was the most cost-effective alternative in one
study [28]. If the most cost-effective delivery method
was unavailable, in five of the six studies including more
than one delivery method of FMT, alternative delivery
methods were also considered cost-effective compared
with the antibiotic treatments [26–30]. Additional file 3
presents an overview of the cost-effectiveness of the dif-
ferent delivery methods of FMT.
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Methodological quality assessment
The methodological quality of each study was evaluated
according to the Drummond ten-point checklist for
assessing economic evaluations [16]. The overall evalu-
ation is presented in Table 1. Detailed assessments of
each article are available in Additional file 4, and a table
containing the inputs applied in the analyses is provided
in Additional file 5.
Research aim and choice of alternatives
Except for one study [27], a precise aim was reported in
all studies including a description of the alternatives,
Fig. 1 Study selection flow-chart. The chart is adapted from the PRISMA-guidelines for reporting of systematic reviews [20]
Table 1 Results of the quality assessment of health economic evaluations














Question 1. Research aim Yes Yes Yes No Yes Yes Yes
Question 2. Alternatives Yes Yes Yes Yes Yes Yes Yes
Question 3. Effectiveness Cannot tell Cannot tell Cannot tell Cannot tell Cannot tell Cannot tell Cannot tell
Question 4. Identification
of costs and consequences
No No Yes Cannot tell No No No
Question 5. Measurement
of costs and consequences
Cannot tell Cannot tell Yes Cannot tell Yes Cannot tell Yes
Question 6. Valuation of
costs and consequences
Cannot tell Cannot tell Yes Cannot tell Yes Cannot tell Yes
Question 7. Extrapolation
and discounting
NA NA Yes Yes NA NA NA
Question 8. Results Yes Yes Yes Yes Yes No Yes
Question 9. Sensitivity analyses Yes Yes Yes No Yes Yes Yes
Question 10. Discussion Cannot tell Cannot tell Yes No Cannot tell Cannot tell Yes
The items reported in the table are based on the main topic of each item in the checklist for assessing economic evaluations reported by Drummond et al., 2015
[16]. The answers reported in the table indicate the compliance with the checklist-item: yes (adequate method), no (not adequate method), cannot tell (unclear)
or not applicable. The complete checklist can be accessed through the original source [16]. NA = not applicable
Hammeken et al. Health Economics Review            (2021) 11:3 Page 4 of 8
patient population, time horizon and the perspective from
which the analysis was conducted (Q1). The alternative
treatments were sufficiently described to understand the
field of research; and, according to international treatment
guidelines [6, 7], the alternatives were meaningful treat-
ments for patients with rCDI (Q2).
Effectiveness estimates
The application of effectiveness estimates differed be-
tween the studies. Whereas some separated the inputs
for cure and recurrence of rCDI [24, 28–30], this was
not explicitly done in others [25–27] (Additional file 4).
Differences in the estimates were also observed between
the studies; for example, the probabilities reported for
cure ranged between 87.0 and 94.5% for FMT by colon-
oscopy, 30.8 and 91.6% for oral vancomycin and 42.0
and 93.7% for fidaxomicin. Despite the differences in
cure rates, FMT by colonoscopy was associated with the
highest probability of cure in all studies. Considerable
differences were, however, observed between the studies
regarding the order of the probabilities of cure applied
for other alternatives.
Generally, the estimates of effectiveness were based on
evidence of varying quality including RCTs, cohort stud-
ies and case series. Moreover, none of the studies ad-
equately described how the parameter estimates for
effectiveness were identified, selected and pooled for the
analyses. Only one study included documentation of a
pragmatic literature search as a basis for identifying
model inputs; however, information on the choice of
specific sources and pooling of estimates were not pro-
vided [30] (Q3). Apart from one study, which included a
head-to-head comparison trial of the two included alter-
natives [27], all of the health economic evaluations
seemed to have applied unadjusted indirect comparisons
of the alternatives.
Cost and consequences
Five studies applied a time horizon of ≤1 year in the ana-
lyses [24, 25, 28–30], which limits assessment of all the
relevant consequences of treatment alternatives when
QALYs are used as the outcome measure. Moreover, all
but one study applied utility estimates for rCDI from
non-RCDI patient populations, e.g. patients with inflam-
matory bowel disease or non-infectious diarrhoea, due
to lack of evidence on utility estimates for patients with
rCDI. The applied utility estimates for rCDI varied
greatly from 0.42 to 0.88, whereas the differences be-
tween rCDI patients and healthy people ranged from
0.06 to 0.36 (Additional file 4). One study reported a
higher utility weight for patients with rCDI than for
healthy people [27]. The most recent study applied a
utility weight for rCDI based on patients with CDI and a
utility weight for the healthy state based on general
population norms [30]. This produced a larger difference
in utility estimates between rCDI patients and healthy
people than in the other articles (Q5/Q6).
The studies reported various perspectives for their
analyses. Two of the articles stated that a societal per-
spective was applied [24, 28]. Nevertheless, in all studies,
the costs seemed to be restricted to healthcare costs.
Measurement and valuation of costs were generally not
reported separately, and parameter estimates were drawn
from a variety of sources including national fee sched-
ules, previous research studies and micro-costing based
on FMT protocols. Considerable differences were ob-
served between the studies regarding the cost estimates
applied for each treatment alternative; for example, the
cost ranged between 840 GBP and 3158 GBP for FMT
by colonoscopy, 203 GBP and 515 GBP for oral vanco-
mycin, and 1368 GBP and 3155 GBP for fidaxomicin.
For FMT, the cost-estimates were based on a variety of
assumptions regarding the resource use associated with
the treatment. Oral vancomycin or pulse-taper vanco-
mycin was the least costly treatment alternative in most
of the studies (n = 5) [24, 26–28, 30], whereas FMT by
colonoscopy was the least costly in one study [25], and
FMT by capsules was the least costly in another study
[29]. The most expensive treatment was either fidaxomi-
cin (n = 2) [24, 29], FMT by colonoscopy (n = 3) [27, 28,
30], FMT by enema (n = 1) [26] or pulse-taper vanco-
mycin (n = 1) [25]. The inclusion of the risks and costs
of adverse events and hospital admissions varied be-
tween the studies (Q5/Q6) (Additional file 4). Costs
were extrapolated to a specific reference year in each
study, and discounting was used to adjust for differential
timing if applicable, e.g. in studies with a time horizon
exceeding 1 year [26, 27] (Q7).
Results and sensitivity analyses
In most of the studies, the incremental cost-effectiveness
ratio (ICER) was the primary outcome of the analysis.
ICERs were calculated if none of the alternatives com-
pared were considered dominant. In one study, however,
an ICER was calculated between FMT by colonoscopy
and FMT by oral capsules even though FMT by colonos-
copy seemed to be dominant [29] (Q8). All studies ap-
plied probabilistic sensitivity analyses, and all but one
study included deterministic sensitivity analyses to char-
acterise parameter uncertainties [27]. Examination of
methodological and structural uncertainty or heterogen-
eity was limited. In addition, the studies generally did
not provide sufficient descriptions and justifications for
the choice of estimates used in the sensitivity analyses.
High probabilities that the FMT alternatives were cost-
effective compared with antibiotics were found in the
probabilistic sensitivity analyses [25–30], but the choice
of delivery method was associated with some uncertainty
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[26–30] (Q9). Lastly, the studies varied with regards to
their discussion of study limitations, generalisability and
the need for future research (Q10).
Discussion
In this study, we found that FMT was considered cost-
effective in all of the included health economic evalua-
tions. FMT was both cost-saving and more effective than
antibiotics in five of the seven identified studies. Al-
though the conclusions varied concerning the most cost-
effective delivery method of FMT in all but one study,
other delivery methods were still cost effective compared
with antibiotic treatments if the preferred method of de-
livery was unavailable.
The study characteristics differed with regard to ana-
lytic method, time horizon, perspective, patient popula-
tion, number of previous rCDIs, treatment alternatives
and the willingness-to-pay threshold applied in the ana-
lyses. We identified several methodological concerns
that may potentially impact the conclusions of the stud-
ies: the choice of effectiveness estimates, the time hori-
zon used in the analysis and the selection of utility and
cost estimates.
The reporting of methods used to identify, select and
pool parameter estimates for effectiveness was sparse.
Without this information, it becomes difficult to judge
the validity and applicability of the data included in the
analyses and to determine how any biases may impact
the results [20]. In this systematic review, we found that
the effectiveness measures were based on mixed quality
evidence and unadjusted indirect comparisons, possibly
resulting in biased estimates. Nonetheless, in all studies,
at least one of the FMT delivery methods was associated
with a higher probability of cure than all of the antibiotic
treatment alternatives. This is in accordance with three
out of four RCTs investigating the efficacy of FMT com-
pared with vancomycin [12, 13] and fidaxomicin [14], in
which a substantial benefit of FMT (> 39 percentage
points) was identified, thereby supporting the validity of
the findings of FMT being a cost-effective alternative.
Five studies applied a relatively short time-horizon of
≤1 year in their analyses [24, 25, 28–30]. In general, the
time horizon should be sufficiently long to capture all
differences in cost and effects [16]. Studies have found
that patients with CDI have a significantly higher mor-
tality risk than patients without CDI [31, 32]. Because
FMT is expected to have a higher probability of cure
than alternative treatment modalities [12–14], patients
who receive FMT will, on average, spend less time with
CDI than patients treated with other alternatives and
thus have a lower risk of dying from CDI. In order to
obtain valid cost-effectiveness estimates, this mortality
risk difference should be included in the analysis. When
QALYs are used as the outcome measure, a short time
horizon will most likely not include all of the associated
benefits of FMT; and in terms of cost-effectiveness, the
results will therefore be biased in favour of antibiotic
treatments. Consequently, all other things being equal,
FMT may even be more cost-effective than presented in
the studies that applied a short time horizon.
The QALY estimate is also affected by the chosen
rCDI utility weights. In six studies, the utility weights
were drawn from patients with other conditions than
rCDI [24–29]. Recent studies have published utility esti-
mates for patients hospitalised with an index or recur-
rent CDI measured by the EuroQol 5-Dimensions 3-
Level (EQ-5D-3L)-questionnaire [33, 34]. The only health
economic evaluation applying a CDI-specific utility weight
[30] based its input on a UK study by Wilcox et al. [33] in
which the authors estimated a utility weight of 0.42 for pa-
tients with CDI. A recent French study [34] estimated a
utility weight of 0.05 which indicates that substantial vari-
ations may exist among patients with CDI. All of these
values are significantly lower than the values applied in
the remaining health economic evaluations [24–29]. As
discussed previously, patients treated with FMT are ex-
pected to spend less time with CDI than patients treated
with alternatives to FMT. A larger difference in utility
weights between healthy patients and patients with CDI
would, therefore, lead to FMT being even more cost-
effective than concluded in most of the studies. However,
a multinational study by Heinrich et al. [35] based on the
36-item Short Form Health Survey (SF-36) found a utility
weight of 0.58 and 0.64 in patients with a current and pre-
vious CDI episode, respectively. This difference between
CDI and “healthy” patients is smaller than the differences
applied in most of the health economic evaluations.
Though even if this narrow difference was applied, FMT
would produce a higher accumulation of QALYs than less
effective alternatives and, all other things being equal,
FMT would still be the dominant treatment option in the
five identified studies in which FMT was associated with
lower costs [25–27, 29, 30].
When considering the costs of FMT, the procedure
may be divided into three elements: donor recruitment
and screening, laboratory processing, and clinical appli-
cation and follow-up [36]. Currently, these elements vary
from one setting to another [37]. This variability may
affect both the resource use and effectiveness of FMT,
and different processes may, therefore, produce different
cost-effectiveness estimates. In some of the studies in-
cluded in this systematic review, the FMT process was
not described in detail, limiting the applicability of the
study results in other specific clinical settings. In
addition, large variations in the cost estimates for both
FMT alternatives and antibiotic treatment alternatives
were observed between the health economic evaluations.
The cost estimate for a single treatment with the FMT
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alternatives was higher than for a single treatment with
vancomycin in most of the studies. Even so, owing to
the increased effectiveness of FMT, which yields a more
limited risk of recurrence and its associated costs, all
studies concluded that FMT is a cost-effective treatment
for rCDI, and some studies reported that FMT may even
be cost saving compared with antibiotic treatment
alternatives.
In the present study, we performed a systematic litera-
ture search in several databases and included methodo-
logical quality assessment of the included studies.
Quality assessments are subjective evaluations [38] and
our results might therefore not be consistent with those
of others. Yet, the quality assessments in this study were
conducted by two authors who agreed on the final evalu-
ation, and to enhance the transparency of our assess-
ment, we present a detailed quality assessment of each
of the studies in Additional file 4.
Future research on the cost-effectiveness of FMT
should improve the quality of reporting to aid an assess-
ment of the methodological quality as well as the applic-
ability and generalisability of the analyses. The use of
acknowledged methods for identification and synthesis
of effectiveness estimates and the use of a life-long time-
horizon to capture all relevant costs and consequences
would increase confidence in the results of health eco-
nomic evaluations based on decision analytic modelling.
Moreover, there is a need for additional primary re-
search on the health-related quality of life of patients
with rCDI to inform future cost-utility analyses.
Conclusions
FMT is reported as a highly cost-effective treatment al-
ternative compared with antibiotic treatments for pa-
tients with rCDI. The identified health economic
evaluations varied with respect to many study character-
istics and several methodological concerns applied. Con-
sidering that recent RCTs have found FMT to be a
substantially more effective treatment for rCDI than an-
tibiotics, these concerns do, however, not seem to
change the conclusion regarding cost-effectiveness. Still,
due to the unstandardised nature of FMT, decision-
makers should be aware that the magnitude of costs and
effects of FMT may be context specific. Based on the
currently available evidence, increased implementation
of FMT for rCDI treatment in clinical practice should be
strongly considered.
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